At GARDP North America, we develop innovative partnerships to guard the power of antibiotics, so that modern medicine works for you.
THE VALUE OF A NON-PROFIT PARTNERSHIP
Founded in 2021, GARDP North America drives innovative solutions to antibiotic resistance in North America. As a member of the Global Antibiotic Research & Development Partnership’s network, we pursue the common goal of accelerating the development and availability of much-needed antibiotic treatments.
We harness the best of public and private sector resources, capacities, and scientific expertise. As a non-profit, we can place public health needs ahead of commercial returns. We work with public and private partners on late-stage drug development. We bring our expertise to the conduct of clinical trials, even in hard-to-reach geographic areas. We further support drug manufacturing and ensure treatments reach the people who need them most.
Partnerships are at the heart of our success in developing new and improved treatments. We are extremely grateful for the commitment of GARDP’s funders in supporting our work to develop new treatments to address the urgent health crisis of antibiotic resistance. Thank you.
GARDP NORTH AMERICA BOARD MEMBERS
Andrew is an attorney with legal and strategic policy expertise in international access to medical technologies and health equity issues, global health policy, intellectual property (IP), and trade. Andrew received a B.A. from Princeton University, an M.A. from Columbia University, and a J.D. from the University of Maryland School of Law.
GARDP NORTH AMERICA TEAM
Suba is an experienced infectious disease physician with extensive industry and public health experience. Educated in India, Suba has lived in the U.S. for the last 30 years. She has worked in clinical and public health practice, and has had a number of senior medical and pharmacovigilance roles in drug development in companies such as Pfizer, BMS, and Alexion Pharmaceuticals.